Charles Schwab Investment Management Inc. Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Charles Schwab Investment Management Inc. raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 7.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 565,503 shares of the company’s stock after acquiring an additional 39,850 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.96% of Protagonist Therapeutics worth $25,448,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in PTGX. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Protagonist Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock worth $95,000 after purchasing an additional 379 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Protagonist Therapeutics by 749.2% during the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after purchasing an additional 487 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth about $43,000. CWM LLC boosted its stake in shares of Protagonist Therapeutics by 910.3% during the 3rd quarter. CWM LLC now owns 1,273 shares of the company’s stock worth $57,000 after purchasing an additional 1,147 shares during the last quarter. Finally, Segall Bryant & Hamill LLC boosted its stake in shares of Protagonist Therapeutics by 1.5% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 120,301 shares of the company’s stock worth $5,414,000 after purchasing an additional 1,739 shares during the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on PTGX shares. Truist Financial started coverage on shares of Protagonist Therapeutics in a research note on Monday, September 9th. They set a “buy” rating and a $60.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. TD Cowen raised shares of Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. Wedbush reissued an “outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. Finally, StockNews.com raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $53.57.

Insider Buying and Selling at Protagonist Therapeutics

In other news, insider Arturo Md Molina sold 1,906 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $40.98, for a total transaction of $78,107.88. Following the sale, the insider now owns 46,444 shares in the company, valued at $1,903,275.12. This trade represents a 3.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William D. Waddill sold 8,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the sale, the director now owns 12,000 shares in the company, valued at $540,000. This represents a 40.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 232,066 shares of company stock valued at $10,681,738 over the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Up 2.7 %

Shares of PTGX stock opened at $41.68 on Friday. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of 15.67 and a beta of 2.18. Protagonist Therapeutics, Inc. has a fifty-two week low of $19.00 and a fifty-two week high of $48.89. The firm’s 50 day moving average price is $44.81 and its two-hundred day moving average price is $40.06.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.